Researcher

Satoshi Ikeda

Kansai Medical University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 11, 2026 · JOURNAL ARTICLE

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

International Journal of Clinical Oncology

Rigorous phase 3 pooled analysis demonstrating a clinically meaningful OS benefit (HR 0.46) with durable 5-year survival gains in a population with high unmet need and poor prognosis, though sample size in the Japanese subgroup is modest.

Strong EvidenceYasushi Goto Hideaki Mizutani Lung Cancer Treatments and Mutations

Reported

Overall survival (median)41.0 vs 15.2 months

Overall survival hazard ratio0.46

Overall survival HR 95% CI0.27–0.78

AUG 7, 2026 · JOURNAL ARTICLE

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

Cancer Science

A large retrospective cohort study documenting real-world trends in biomarker testing adoption and treatment patterns in advanced NSCLC, confirming expected shifts toward multigene testing while identifying a persistent care gap.

Important Confirmatory EvidenceCancer Genomics and Diagnostics Takayuki Takahama Lung Cancer Treatments and Mutations

Reported

Sample size24047

Study periodApril 2019 to May 2024

Number of hospitals300